Description
PD-1: PD-L2 [Biotinylated] Inhibitor Screening ELISA Kit | EP-154| Gentaur Distribution US, UK & Europe
Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
Source: Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
Molecule: PDN/A1.
Format: Solid.
Species: Human.
Application: This kit is developed for screening for inhibitors of human PD-1 binding to human PD-L2.
Kit Component: This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-L2 to immobilized human PD-1 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated PD-L2 protein, a human PD-1 protein, an anti-PD1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.
Stability: The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Storage Conditions: 2-8℃.
Shipping Conditions: RT